Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19)

COVID-19 Clinical Trial

— VOC-COVID  

Official title:

Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by (SARS-CoV-2): Predictive Interest in Short-term Evolution

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04379154
• Other study ID #: 2020_0060
• Status: Completed
• Phase: N/A
• Start date: April 14, 2020
• Est. completion date: June 1, 2021

Study information

• Verified date: January 2022
• Source: Hopital Foch
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study of volatile organic compounds (VOCs) detected in exhaled air is an innovative research area for respiratory diseases. This analysis can be done by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOCs without identifying them. The VOCs in exhaled air in patients hospitalized for COVID-19 infection are analysed in this study, using electronic noses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: June 1, 2021
• Est. primary completion date: June 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients infected by SARS-CoV-2 whose medical condition warrants hospitalisation (out of intensive care) for oxygen therapy less or equal to 4 l/min

• Patients must be 18 years of age or older

• Fluent in the French language

• Have signed a consent form

• Being affiliated with healthcare insurance

Exclusion Criteria:

• Pregnant woman

• Patient deprived of liberty by judicial or administrative decision

Related Conditions & MeSH terms

• COVID-19

Intervention

Device:
• Volatile Organic Compounds analysis
Volatile Organic Compounds analysis in exhaled air by electronic noses

Locations

Country	Name	City	State
France	Hôpital Foch	Suresnes

Sponsors (1)

Lead Sponsor	Collaborator
Hopital Foch

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Profiles of volatile organic compounds (VOCs) in exhaled air between 2 health conditions	Comparison of variation of profiles of Volatile Organic Compounds in exhaled air from electronic noses (a set of sensors interacting with the VOCs exhaled). The analysis of the generated signal (resistance or load variations) is characteristic of the composition of VOCs), between patients who improve and patients who get worse during their hospitalisation for COVID-19 infection	1 day
Secondary	Profiles of volatile organic compounds (VOCs) in exhaled air on 1 health condition	Comparison of variation of profiles of Volatile Organic Compounds in exhaled air from electronic noses (a set of sensors interacting with the VOCs exhaled. The analysis of the generated signal (resistance or load variations) is characteristic of the composition of VOCs), between the start and the discharge to the hospital in patients infecting and recovering from COVID-19.	2 weeks
Secondary	Profiles of volatile organic compounds (VOCs) in exhaled air between 2 periods	Comparison of variation of profiles of Volatile Organic Compounds in exhaled air from electronic noses (a set of sensors interacting with the VOCs exhaled. The analysis of the generated signal (resistance or load variations) is characteristic of the composition of VOCs), between the hospitalisation period and a post-hospitalisation follow-up consultation in patients infected by COVID-19 and recovered.	4 months
Secondary	Profiles of volatile organic compounds (VOCs) in exhaled air by mass spectrometry at each visit based on patient evolution status.	Comparison of variation of profiles of Volatile Organic Compounds in exhaled air from mass spectrometry, at hospitalisation, post-hospitalisation and follow-up consultation in patients infected by COVID-19 and recovered.	4 months